1 research outputs found

    IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>A recent in vitro study indicates that IGOB131, a novel seed extract of the traditional West African food plant <it>Irvingia gabonensis</it>, favorably impacts adipogenesis through a variety of critical metabolic pathways including PPAR gamma, leptin, adiponectin, and glycerol-3 phosphate dehydrogenase. This study was therefore aimed at evaluating the effects of IGOB131, an extract of <it>Irvingia gabonensis</it>, on body weight and associated metabolic parameters in overweight human volunteers.</p> <p>Methods</p> <p>The study participants comprised of 102 healthy, overweight and/or obese volunteers (defined as BMI > 25 kg/m<sup>2</sup>) randomly divided into two groups. The groups received on a daily basis, either 150 mg of IGOB131 or matching placebo in a double blinded fashion, 30–60 minutes before lunch and dinner. At baseline, 4, 8 and 10 weeks of the study, subjects were evaluated for changes in anthropometrics and metabolic parameters to include fasting lipids, blood glucose, C-reactive protein, adiponectin, and leptin.</p> <p>Results</p> <p>Significant improvements in body weight, body fat, and waist circumference as well as plasma total cholesterol, LDL cholesterol, blood glucose, C-reactive protein, adiponectin and leptin levels were observed in the IGOB131 group compared with the placebo group.</p> <p>Conclusion</p> <p><it>Irvingia gabonensis </it>administered 150 mg twice daily before meals to overweight and/or obese human volunteers favorably impacts body weight and a variety of parameters characteristic of the metabolic syndrome. This is the first double blind randomized placebo controlled clinical trial regarding the anti-obesity and lipid profile modulating effects of an <it>Irvingia gabonensis </it>extract. The positive clinical results, together with our previously published mechanisms of gene expression modulation related to key metabolic pathways in lipid metabolism, provide impetus for much larger clinical studies. <it>Irvingia gabonensis </it>extract may prove to be a useful tool in dealing with the emerging global epidemics of obesity, hyperlipidemia, insulin resistance, and their co-morbid conditions.</p> <p>Trial registration</p> <p>ClinicalTrials.gov NCT00645775</p
    corecore